Chapter 13
Transarterial Embolization for Patients with Hepatocellular Carcinoma
Jordi Bruix MD,
Carmen Ayuso MD,
Maria I. Real MD,
Jordi Bruix MD
Senior Consultant
Barcelona-Clinic-Liver-Cancer (BCLC) Group, Liver Unit and Radiology Department, Hospital Clínic, University of Barcelona, Centro de Investigaciones Biomédicas en Red, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorCarmen Ayuso MD
Senior Consultant
Barcelona-Clinic-Liver-Cancer (BCLC) Group, Liver Unit and Radiology Department, Hospital Clínic, University of Barcelona, Centro de Investigaciones Biomédicas en Red, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorMaria I. Real MD
Barcelona-Clinic-Liver-Cancer (BCLC) Group, Liver Unit and Radiology Department, Hospital Clínic, University of Barcelona, Centro de Investigaciones Biomédicas en Red, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorJordi Bruix MD,
Carmen Ayuso MD,
Maria I. Real MD,
Jordi Bruix MD
Senior Consultant
Barcelona-Clinic-Liver-Cancer (BCLC) Group, Liver Unit and Radiology Department, Hospital Clínic, University of Barcelona, Centro de Investigaciones Biomédicas en Red, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorCarmen Ayuso MD
Senior Consultant
Barcelona-Clinic-Liver-Cancer (BCLC) Group, Liver Unit and Radiology Department, Hospital Clínic, University of Barcelona, Centro de Investigaciones Biomédicas en Red, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorMaria I. Real MD
Barcelona-Clinic-Liver-Cancer (BCLC) Group, Liver Unit and Radiology Department, Hospital Clínic, University of Barcelona, Centro de Investigaciones Biomédicas en Red, Institut d' Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Barcelona, Spain
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Therapeutic strategy in patients with hepatocellular carcinoma and role of transarterial chemoembolization
-
Techniques to obstruct the hepatic artery blood flow
-
Therapeutic efficacy of transarterial (chemo)embolization: impact on tumor progression and survival
-
Transarterial embolization as coadjuvant treatment prior to resection and transplantation
-
Conclusion
-
Self-assessment questions
-
References
-
Self-assessment answers
References
- Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36.
- Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519–24.
- Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–9.
- Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429–42.
- Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164–71.
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–9.
- Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434–40.
- Yao FY, Kerlan RK Jr, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819–27.
- Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
- Sato Y, Fujiwara K, Furui S, et al. Benefi t of transcatheter arterial embolization for ruptured hepatocellular carcinoma complicating liver cirrhosis. Gastroenterology 1985; 89: 157–9.
- Kanematsu T, Inokuchi K, Sugimachi K, et al. Selective effects of Lipiodolized antitumor agents. J Surg Oncol 1984; 25: 218–26.
-
Konno T, Maeda H, Iwai K, et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 1984; 54: 2367–74.
10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18: 365–76.
- Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1 ): S179–S188.
- Makuuchi M, Sukigara M, Mori T, Kobayashi J, Yamazaki S, Hasegawa H et al. Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology 1985; 156: 331–4.
- Chuang VP, Wallace S, Soo CS, Charnsangavej C, Bowers T. Therapeutic Ivalon embolization of hepatic tumors. AJR Am J Roentgenol 1982; 138: 289–94.
- Ito K, Kusunoki H, Okamoto E, et al. Intra-arterial alcoholization of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33 (Suppl): S42–S47.
- Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol 1997; 24 (2 Suppl 6 ): S6.
- Bruix J, Castells A, Montanya X, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 1994; 20: 643–50.
- Kwok PC, Lam TW, Chan SC, et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000; 32: 955–64.
- Nakao N, Miura K, Takahashi H, et al. Hepatocellular carcinoma: combined hepatic, arterial, and portal venous embolization. Radiology 1986; 161: 303–7.
- Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and effi cacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653–9.
-
Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and effi cacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997; 79: 2087–94.
10.1002/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- Castells A, Bruix J, Ayuso C, et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22: 410–5.
- Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12: 321–6.
- Bartolozzi C, Lencioni R, Caramella D, Falaschi F, Cioni R, DiCoscio G. Hepatocellular carcinoma: CT and MR features after transcatheter arterial embolization and percutaneous ethanol injection. Radiology 1994; 191: 123–8.
-
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256–61.
- Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578–83.
-
Ikeda K, Kumada H, Saitoh S, Arase Y, Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68: 2150–4.
10.1002/1097-0142(19911115)68:10<2150::AID-CNCR2820681011>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994; 19: 1115–23.
- Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 129–34.
- Stuart K. Chemoembolization in the management of liver tumors. Oncologist 2003; 8: 425–37.
- Takayasu K, Suzuki M, Uesaka K, et al. Hepatic artery embolization for inoperable hepatocellular carcinoma; prognosis and risk factors. Cancer Chemother Pharmacol 1989; 23 (Suppl): S123–S125.
- Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8: 1108–14.
- Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 1991; 13: 427–33.
-
Yamashita Y, T akahashi M, Koga Y, et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 1991; 67: 385–91.
10.1002/1097-0142(19910115)67:2<385::AID-CNCR2820670212>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224–9.
-
Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994; 74: 2449–53.
10.1002/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- Chen MS, Li JQ, Zhang YQ, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002; 8: 74–8.
- Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995; 195: 747–52.
- Ikeda K, Saitoh S, Suzuki Y, et al. A prospective randomized administration of 5 ′-deoxy-5-fl uorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1997; 20: 202–8.
- Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989; 97: 965–71.
- Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma–a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (fi rst cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992; 31 (Suppl): S1–S6.
- Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma–a randomized controlled trial. Gastroenterology 1988; 94: 453–6.
- Okamura J, Kawai S, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma–a comparison of L-TAE with Farmorubicin and L-TAE with adriamycin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992; 31 (Suppl): S20–S24.
- Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181–4.
- Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: effi cacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81.
- Nagasue N, Galizia G, Kohno H, et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 1989; 106: 81–6.
- Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P'eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 122–6.
- Louha M, Poussin K, Ganne N, et al. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology 1997; 26: 998–1005.
- Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of the preventive effect of pre-operative transcath-eter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996; 87: 206–11.
- Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–30.
- Majno PE, Adam R, Bismuth H, et al. Infl uence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688–701.
- Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123–8.
- Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073–9.
- Kawai S, Tani M, Okamura J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma–a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1994; 33 (Suppl): S97–102.
